Related Experiment Video

Updated: May 30, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors

Oni J Blackstock1, Karen H Wang, David A Fiellin

  • 1Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, CT, USA.

Journal of General Internal Medicine
|August 13, 2011
PubMed

Insights

AIDS Drug Assistance Programs (ADAPs) show inconsistent coverage for crucial cardiovascular risk factors in people with HIV. Ensuring consistent formulary coverage is vital for managing these conditions and improving patient health outcomes.

Area of Science:

  • Public Health
  • HIV/AIDS Management
  • Cardiovascular Disease Prevention

Background:

  • Cardiovascular disease (CVD) mortality is rising among people with HIV in the U.S.
  • Many individuals with HIV rely on state-run AIDS Drug Assistance Programs (ADAPs) for essential medications.
  • ADAP coverage for non-HIV medications lacks federal mandates, leading to variability.

Purpose of the Study:

  • To evaluate the consistency of ADAP coverage for key cardiovascular risk factors against established clinical guidelines.
  • The study focused on type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation.
  • Clinical guidelines were used as the benchmark for assessing the standard of care.

Main Methods:

  • A cross-sectional survey was conducted on the formularies of 53 state and territorial ADAPs.
  • Coverage consistency was categorized as 'consistent' (all first-line drugs covered), 'partially consistent' (some first-line drugs covered), or 'no coverage'.
  • The assessment focused on first-line drug coverage for specific cardiovascular risk factors.

Main Results:

  • Only 7.5% of ADAPs offered consistent coverage for all four surveyed cardiovascular risk factors.
  • Coverage varied significantly, with 68% providing at least partial consistency for one or more factors.
  • Many ADAPs lacked first-line treatment coverage, particularly for hypertension (60%) and type 2 diabetes (51%). Statins were most commonly covered (66%), while nicotine replacement therapies were least common (9%).

Conclusions:

  • There is wide variability in ADAP coverage for cardiovascular risk factors, falling short of clinical guidelines.
  • Given the increasing lifespan of HIV-infected individuals and budget constraints, aligning ADAP coverage with guidelines is recommended.
  • Consistent formulary coverage is crucial for managing cardiovascular health in the growing HIV-infected population.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...